AhR and FcγRIIB could be SIRT1 therapeutic targets in SLE to avoid side effects of anti-inflammatory and steroids synthetic cortisone medications and to solve the problem that current treatments do not lead to improved curative effect for severe patients. Here, AHR is linked to systemic lupus erythematosus.